Cutaneous arteritis during olaparib treatment for ovarian cancer

被引:2
|
作者
Iinuma, Shin [1 ]
Takahashi, Chiaki [1 ]
Negishi, Hideaki [2 ]
Ishida-Yamamoto, Akemi [3 ]
机构
[1] Japanese Red Cross Kitami Hosp, Dept Dermatol, Kitami, Hokkaido, Japan
[2] Japanese Red Cross Kitami Hosp, Dept Obstet & Gynecol, Kitami, Hokkaido, Japan
[3] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Hokkaido, Japan
来源
JOURNAL OF DERMATOLOGY | 2021年 / 48卷 / 03期
关键词
D O I
10.1111/1346-8138.15749
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
引用
收藏
页码:E140 / E141
页数:2
相关论文
共 50 条
  • [11] Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
    Montemorano, Lauren
    Lightfoot, Michelle D. S.
    Bixel, Kristin
    ONCOTARGETS AND THERAPY, 2019, 12 : 11497 - 11506
  • [12] Olaparib in the management of ovarian cancer
    Bixel, Kristin
    Hays, John L.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2015, 8 : 127 - 135
  • [13] Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
    Bangham, Madeleine
    Goldstein, Robert
    Walton, Henry
    Ledermann, Jonathan A.
    GYNECOLOGIC ONCOLOGY REPORTS, 2016, 18 : 22 - 24
  • [14] Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
    Chen, Qian
    Li, Xiaoli
    Zhang, Zhen
    Wu, Tong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [15] Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
    Shaw, Heather M.
    Hall, Marcia
    ONCOTARGETS AND THERAPY, 2013, 6 : 1197 - 1206
  • [16] Olaparib Approved for Advanced Ovarian Cancer
    不详
    CANCER DISCOVERY, 2015, 5 (03) : 218 - 218
  • [18] Olaparib recommendations for ovarian cancer patients
    Johnson, Peter
    FUTURE ONCOLOGY, 2016, 12 (02) : 149 - 151
  • [20] Olaparib in ovarian cancer with BRCA mutation
    Pujade-Lauraine, Eric
    Combe, Pierre
    BULLETIN DU CANCER, 2015, 102 (06) : S82 - S84